Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

GR1803 Injection in Patients With RRMM — Stella

Home/Multiple Myleoma/GR1803 Injection in Patients With RRMM

View on ClinicalTrials.gov

Recruiting

Back to Multiple Myleoma trials

GR1803 Injection in Patients With RRMM

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Safety & dosing

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Enrollment target

~30 participants

Started

April 2025

Primary completion

July 2027

Age range

18 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.